000			03313cam a2200349 a 4500
003			EG-GiCUC
005			20250223031935.0
008			180227s2017 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.33.M.Sc.2017.Di.A
100	0		_aDina Mahmoud Mohamed Gabr
245	1	0	_aAssessment of response to sofosbuvir-based triple therapy versus sofosbuvir-based dual therapy in chronic HCV treatment experienced patients / _cDina Mahmoud Mohamed Gabr ; Supervsed Ahmed Fouad Soliman , Marwa Khairy Mehasseb , Rabab Muhamed Maher
246	1	5	_aتقيم الاستجابه للعلاج الثلاثي القائم علي عقار السوفوسبفير في مقابل العلاج الثنائي في مرضي الالتهاب الكبدي الفيروسي المزمن (س) الذين سبق لهم العلاج بالانتيرفيرون طويل المفعول و الريبافيرين
260			_aCairo : _bDina Mahmoud Mohamed Gabr, _c2017
300			_a73 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine
520			_aBackground: HCV is a major public health in Egypt carrying many complications. Treatment with pegylated interferon and ribavirin was associated with many contraindications and complications as well as modest sustained virological response (SVR). With the emergence of sofosbuvir based treatment regimens the SVR markedly improved even with treatment experienced (pegylated interferon/ribavirin) patients. Aim of the work: Assessment of the response ofsofosbuvir based dual therapy versussofosbuvir based triple therapy in pegylated interferon/ribavirin experienced patients. Patients and methodology: this study was conducted on 200 HCV treatment experienced patients divided into two groups; Group (1): received dual therapy (SOF+RBV) for 24 weeks and group (2): received triple therapy (SOF+RBV+PEG-IFN) for 12 weeks. Both groups were compared regarding baseline characteristics, rapid virological response (RVR), end of treatment response (ETR) and SVR and side effects. Results: Males represented 65% of the studied population (p value 0.003), 14.5% were cirrhotic and 18% were diabetics. Significant drop of serum transaminases level was reported in both groups during the treatment. Significant rise of bilirubin level and decline of hemoglobin were reported with ribavirin use in both groups. RVR (group (1) 95%, group (2) 99%) and ETR (group(1) 98%, group (2) 100%) were comparable in both groups. SVR was significantly higher in group (2)(triple therapy) 96% than group (1) (dual therapy) 79% with p value 0.001. Conclusion: SVR of triple therapy (SOF+RBV+PEG-IFN) for 12 weeks in chronic PEG-IFN and RBV experienced HCV patients is better than dual therapy (SOF+RBV) for 24weeks
530			_aIssued also as CD
653		4	_aChronic HCV
653		4	_aDual therapy
653		4	_aTriple therapy
700	0		_aAhmed Fouad Soliman , _eSupervisor
700	0		_aMarwa Khairy Mehasseb , _eSupervisor
700	0		_aRabab Muhamed Maher , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c65203 _d65203